AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2020

Feb 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2020-02-14

Reporting Person: Hirsch Andrew (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-16	Common stock	M	2750	—	Acquired	15127	Direct
2020-02-18	Common stock	F	886	$52.01	Disposed	14241	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-14	Restricted stock units	$	A	12000	Acquired		Common stock (12000.0)	Direct
2020-02-14	Stock option (right to buy)	$51.51	A	45000	Acquired	2030-02-14	Common stock (45000.0)	Direct
2020-02-16	Restricted stock units	$	M	2750	Disposed		Common stock (2750.0)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.

F3: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F4: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.